Testing whether DNA repair changes affect radium-223 response
Part of Cancer, Kidney & urinary clinical trials.
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of prostate cancer
- Your prostate cancer is castration-resistant (it’s still active despite low testosterone)
- You have spread to the bones seen on scans and you have symptoms
- Your doctor plans to treat you with radium-223
- Your PSA is 10 or higher, and your expected survival is more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
This study uses special scans (SPECT imaging) to see how radium or lutetium treatments move through your body, helping doctors plan better doses. It's for people with advanced prostate cancer (getting Radium-223) or advanced neuroendocrine tumors (getting 177Lu treatments).
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
This trial tests a drug called radium-223 for prostate cancer that has spread to the bonescars. It's for people who have already had a standard combination treatment and need another option. The goal is to see if adding radium-223 can help control the disease.
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
Hear when a new Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.